Dihexa vs VIP
Both Dihexa and VIP are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | Dihexa | VIP |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound (HGF/c-Met-mimetic) | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 8–45 mg orally daily (research-only) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 10 | 24 |
| Categories | cognitive, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.